Posted by on Nov 19, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of adding elotuzumab to lenalidomide and dexamethasone to treat un-responsive multiple myeloma. The main finding was that patients treated with elotuzumab responded better to lenalidomide and dexamethasone. Some background Many patients respond well to treatment for multiple myeloma (MM). However some...

Read More